Literature DB >> 7620021

Capsular types and antibiotic susceptibility of pneumococci isolated from patients in Belgium with serious infections, 1980-1993.

J Verhaegen1, Y Glupczynski, L Verbist, M Blogie, N Verbiest, J Vandeven, E Yourassowsky.   

Abstract

During the 13-year period from 1 November 1980 to 31 January 1993, we received and serotyped a total of 5,619 clinically significant strains of Streptococcus pneumoniae isolated in more than 75 laboratories in Belgium (4,079 [72.6%] were from blood or pleural fluid, 462 [8.2%] were from cerebrospinal fluid, 691 [12.3%] were from middle ear aspirates, and 387 [6.8%] were from various other body fluids). The isolates belonged to 64 of the 84 currently recognized serotypes. Among the 4,722 isolates tested for susceptibility since 1983, 22% were resistant to at least one antimicrobial agent. Resistance to penicillin has slowly increased since 1985 but remained stable at a level of 2%-4% between 1986 and 1993. Of the 119 isolates with reduced penicillin susceptibility, only 23 were fully resistant (MIC, > or = 2 micrograms/mL) and none of these proved to be resistant to cephalosporins. Resistance to erythromycin increased significantly from 5.2% in 1986 to 21.5% in 1993. Resistance to penicillin and erythromycin was also more frequently recognized in a smaller number of capsular types of S. pneumoniae.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7620021     DOI: 10.1093/clinids/20.5.1339

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  9 in total

1.  Two-year surveillance of antibiotic resistance in Streptococcus pneumoniae in four African cities.

Authors:  M Benbachir; S Benredjeb; C S Boye; M Dosso; H Belabbes; A Kamoun; O Kaire; N Elmdaghri
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

2.  Relationship between capsular type, penicillin susceptibility, and virulence of human Streptococcus pneumoniae isolates in mice.

Authors:  E Azoulay-Dupuis; V Rieux; M Muffat-Joly; J P Bédos; E Vallée; C Rivier; R Isturiz; C Carbon; P Moine
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

Review 3.  Evolution of Streptococcus pneumoniae serotypes and antibiotic resistance in Spain: update (1990 to 1996).

Authors:  A Fenoll; I Jado; D Vicioso; A Pérez; J Casal
Journal:  J Clin Microbiol       Date:  1998-12       Impact factor: 5.948

Review 4.  Antibiotic resistant Streptococcus pneumoniae.

Authors:  E J Minton; J T Macfarlane
Journal:  Thorax       Date:  1996-08       Impact factor: 9.139

5.  Patterns of macrolide resistance determinants among community-acquired Streptococcus pneumoniae isolates over a 5-year period of decreased macrolide susceptibility rates.

Authors:  P Oster; A Zanchi; S Cresti; M Lattanzi; F Montagnani; C Cellesi; G M Rossolini
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

6.  Cost-effectiveness analysis of pneumococcal vaccination of adults and elderly persons in Belgium.

Authors:  D De Graeve; G Lombaert; H Goossens
Journal:  Pharmacoeconomics       Date:  2000-06       Impact factor: 4.981

7.  Extremely high incidence of macrolide and trimethoprim-sulfamethoxazole resistance among clinical isolates of Streptococcus pneumoniae in Taiwan.

Authors:  P R Hsueh; L J Teng; L N Lee; P C Yang; S W Ho; K T Luh
Journal:  J Clin Microbiol       Date:  1999-04       Impact factor: 5.948

8.  Antibiotic susceptibility of acute otitis media pathogens in otitis-prone Belgian children.

Authors:  Muriel J P van Kempen; Mario Vaneechoutte; Geert Claeys; Gerda L C Verschraegen; Judith Vermeiren; Ingeborg J Dhooge
Journal:  Eur J Pediatr       Date:  2004-06-15       Impact factor: 3.183

9.  Extremely high prevalence of nasopharyngeal carriage of penicillin-resistant Streptococcus pneumoniae among children in Kaohsiung, Taiwan.

Authors:  C C Chiou; Y C Liu; T S Huang; W K Hwang; J H Wang; H H Lin; M Y Yen; K S Hsieh
Journal:  J Clin Microbiol       Date:  1998-07       Impact factor: 5.948

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.